Physician profile
Thimmiah Kumar
NPI 1629062617
$7,495.30
in general payments reported to CMS, 2019-2025
33 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $829 · 2021: $991 · 2022: $954 · 2023: $1,217 · 2024: $1,229 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,922 · Debt Forgiveness: $20.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,922.42 |
| Debt Forgiveness | $20.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,218.99 | 2019-2025 | |
| Pfizer INC. | $1,008.61 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $549.75 | 2019-2024 | Dificid, Zinplava, Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $514.50 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $376.18 | 2019-2025 | Entyvio |
| Celgene Corporation | $330.74 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $235.21 | 2020-2024 | Linzess |
| Ardelyx, INC. | $191.19 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $190.92 | 2024-2025 | |
| Gilead Sciences, INC. | $177.02 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $172.60 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $167.02 | 2019-2025 | Ocaliva |
| Allergan, INC. | $156.31 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $135.57 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $128.97 | 2020-2024 | Rebyota |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $127.95 | 2021-2025 | Gimoti |
| Novo Nordisk INC | $120.84 | 2025 | Wegovy |
| Janssen Biotech, INC. | $113.33 | 2023 | Stelara |
| Boston Scientific Corporation | $96.66 | 2022 | |
| Redhill Biopharma INC. | $86.75 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $83.51 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $47.82 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $41.43 | 2023 | |
| Organon LLC | $29.45 | 2023 | Renflexis, Hadlima |
| Lucid Diagnostics INC. | $29.11 | 2024 | |
| Lilly USA, LLC | $26.69 | 2024 | Omvoh |
| Exact Sciences Corporation | $24.34 | 2023 | Cologuard Collection Kit |
| Ethicon US, LLC | $21.58 | 2022 | |
| Daiichi Sankyo INC. | $21.21 | 2023 | Injectafer |
| Vivus LLC | $20.74 | 2021-2024 | Qsymia |
| Olympus America INC. | $20.33 | 2024 | |
| Braintree Laboratories, INC. | $16.89 | 2020 | |
| Ucb, INC. | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thimmiah Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.